Artios exercises option to in-license potential first-in-class nuclease development programme Artios Pharma Ltd ("Artios" or "the Company") Artios exercises option to in-license potential first-in-class nuclease development programme Cambridge, UK, 5 March 2018. Artios Pharma, a...

Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors Artios Pharma Ltd. ("Artios" or "the Company") Artios Pharma Appoints Pierre Legault as Chairman of its Board of Directors Industry leader who brings over 35 years of experience in...

Artios Pharma Company Launch and Fundraising of $33.2 Million to Focus on Novel DNA Damage Response (DDR) Cancer Therapies CAMBRIDGE, United Kingdom, Sept. 21, 2016 (GLOBE NEWSWIRE) -- Artios Pharma Ltd., a new private company focussed on developing novel cancer treatments targeting the DNA Damage Response, was officially...